FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Paclitaxel Injection, USP
Status: Discontinuation
»Therapeutic Categories: Oncology

Expand all

Fresenius Kabi USA, LLC (Revised 03/30/2020)

Company Contact Information:
888-386-1300

Presentation Posting Date Related Information
30 mg/5 mL (6 mg/mL) MDV (NDC 63323-763-05) 03/06/2020 Product available. Check wholesalers for inventory or contact Customer Service to place a direct order. Product will be discontinued when inventory is depleted.

HQ Specialty Pharma (New 07/03/2019)

Company Contact Information:
201-857-8290

Presentation Posting Date Related Information
30 mg/5 mL (NDC 44567-504-1) 07/03/2019 Distributed by WG Critical Care. Discontinuance: no longer commercially viable
100 mg/16.7 mL (NDC 44567-505-1) 07/03/2019 Distributed by WG Critical Care. Discontinuance: no longer commercially viable
300 mg/50 mL (6 mg/mL)(NDC 44567-506-1) 07/03/2019 Distributed by WG Critical Care. Discontinuance: no longer commercially viable

Mylan Institutional (New 03/30/2020)

Company Contact Information:
800-796-9526

Presentation Posting Date Related Information
100 mg in 16.7 mL (6 mg/mL), multi-dose vial (NDC 67457-449-17) 11/22/2019 December 2019
30 mg in 5 mL (6 mg/mL), multi-dose vial (NDC 67457-471-52) 03/30/2020 Expected discontinuation October 2020 (short dating)
300 mg in 50 mL (6 mg/mL), multi-dose vial (NDC 67457-434-51) 03/30/2020 Expected discontinuation October 2020 (short dating)

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English